The International journal of pharmacy practice · 2026
Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10 mg in insomnia patients.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chang Eugene, Tejani Aaron M
Аннотация
OBJECTIVE: To assess the rationale for using lemborexant 10 mg as a starting dose or for those with partial response to 5 mg for the management of insomnia.
METHODS: A review of MEDLINE, regulatory reports, and Canadian Agency for Drugs and Technologies in Health data was conducted.
KEY FINDINGS: Lemborexant 10 mg as an initial dose offers minimal improvement in sleep metrics over 5 mg but increases somnolence risk. No evidence supports dose escalation for partial responders to 5 mg.
CONCLUSION: Lemborexant 10 mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.
METHODS: A review of MEDLINE, regulatory reports, and Canadian Agency for Drugs and Technologies in Health data was conducted.
KEY FINDINGS: Lemborexant 10 mg as an initial dose offers minimal improvement in sleep metrics over 5 mg but increases somnolence risk. No evidence supports dose escalation for partial responders to 5 mg.
CONCLUSION: Lemborexant 10 mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.